Individual
Dr. Patrick Soon-Shiong
biotech founder, Cancer Advocate, cancer doctor, cancer immunotherapy pioneer, cancer immunotherapy researcher, cancer researcher, doctor, Entrepreneur, Health Entrepreneur, Immunotherapy, inventor, media owner, philanthropist, Precision Oncology, Publisher, research institute founder, surgeon | Abraxis BioScience, ANKTIVA, Cancer MoonShot 2020 / Cancer Breakthroughs 2020, Chan Soon-Shiong Family Foundation, Chan Soon-Shiong Institute for Medicine, Chan Soon-Shiong Institute of Molecular Medicine, ImmunityBio, Los Angeles Times, NantHealth, NantKwest, NantOmics, NantWorks | San Diego | California | United States
Roles / Typesbiotech founder, Cancer Advocate, cancer doctor, cancer immunotherapy pioneer, cancer immunotherapy researcher, cancer researcher, doctor, Entrepreneur, Health Entrepreneur, Immunotherapy, inventor, media owner, philanthropist, Precision Oncology, Publisher, research institute founder, surgeon
OrganizationsAbraxis BioScience, ANKTIVA, Cancer MoonShot 2020 / Cancer Breakthroughs 2020, Chan Soon-Shiong Family Foundation, Chan Soon-Shiong Institute for Medicine, Chan Soon-Shiong Institute of Molecular Medicine, ImmunityBio, Los Angeles Times, NantHealth, NantKwest, NantOmics, NantWorks
Websitehttps://immunitybio.com/about/
X / Twitterhttps://x.com/DrPatSoonShiong
Wikipediahttps://en.wikipedia.org/wiki/Patrick_Soon-Shiong
Summary
South African-born American surgeon, billionaire biotech entrepreneur, inventor of Abraxane, founder/executive of Immunity Bio/Nant companies, and developer/promoter of ANKTIVA/NANT Cancer Vaccine immunotherapy platforms. Patrick Soon-Shiong is a physician and biotechnology entrepreneur associated with cancer immunotherapy, including immune activation and natural killer cell-related approaches. Patrick Soon-Shiong, M. D.
Details
Patrick Soon-Shiong is a physician and biotechnology entrepreneur associated with cancer immunotherapy, including immune activation and natural killer cell-related approaches.
Patrick Soon-Shiong, M.D. is a South African-born American surgeon, scientist, inventor, biotech entrepreneur, philanthropist, and media owner. He is credited with developing Abraxane, a protein-bound paclitaxel nanoparticle drug used in breast, lung and pancreatic cancers, through Abraxis BioScience. His current cancer ecosystem centers on ImmunityBio, ANKTIVA (N-803/nogapendekin alfa inbakicept-pmln), NANT Cancer Vaccine/Cancer BioShield concepts, natural killer/T-cell activation, and the Chan Soon-Shiong Institute for Medicine. FDA-approved ANKTIVA use is for BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors, in combination with BCG. Broader claims around ANKTIVA/Cancer BioShield for other cancers should be treated as investigational or disputed unless and until label expansion is approved; AP/CBS reported a 2026 FDA warning about misleading promotional claims tied to ANKTIVA podcast/advertising statements.
